Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares Sold by Amalgamated Bank
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares Sold by Amalgamated Bank
Amalgamated Bank cut its position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) by 7.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,765 shares of the company's stock after selling 432 shares during the period. Amalgamated Bank's holdings in Turning Point Therapeutics were worth $155,000 at the end of the most recent quarter.
根據合併銀行提交給美國證券交易委員會的最新Form 13F文件，該行在第一季度將其在Turning Point Treateutics，Inc.(TPTX-GET評級)的頭寸削減了7.0%。該公司在此期間出售了432股後，擁有5765股該公司股票。截至最近一個季度末，合併銀行在Turning Point Treeutics持有的股份價值15.5萬美元。
Other hedge funds have also modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Turning Point Therapeutics by 0.5% in the first quarter. Wellington Management Group LLP now owns 4,030,991 shares of the company's stock worth $108,231,000 after buying an additional 21,337 shares during the last quarter. Vanguard Group Inc. boosted its position in Turning Point Therapeutics by 0.9% during the first quarter. Vanguard Group Inc. now owns 3,913,128 shares of the company's stock worth $105,067,000 after purchasing an additional 35,789 shares in the last quarter. State Street Corp boosted its position in Turning Point Therapeutics by 37.2% during the first quarter. State Street Corp now owns 3,119,926 shares of the company's stock worth $83,770,000 after purchasing an additional 845,408 shares in the last quarter. Federated Hermes Inc. boosted its position in Turning Point Therapeutics by 19.7% during the first quarter. Federated Hermes Inc. now owns 2,075,037 shares of the company's stock worth $55,715,000 after purchasing an additional 341,455 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Turning Point Therapeutics by 5.4% during the first quarter. Goldman Sachs Group Inc. now owns 844,461 shares of the company's stock worth $22,674,000 after purchasing an additional 43,252 shares in the last quarter. 90.33% of the stock is owned by institutional investors and hedge funds.
其他對衝基金也調整了對該公司的持股。惠靈頓管理集團LLP在第一季度將其在Turning Point Treateutics的股份增加了0.5%。惠靈頓管理集團(Wellington Management Group LLP)在上個季度額外購買了21,337股惠靈頓股票後，目前擁有4,030,991股票，價值108,231,000美元。先鋒集團第一季度將其在Turning Point Treateutics的地位提高了0.9%。先鋒集團目前持有3,913,128股該公司股票，價值105,067,000美元，上個季度又購買了35,789股。道富集團在第一季度將其在Turning Point Treeutics的頭寸提高了37.2%。道富銀行目前持有3,119,926股該公司股票，價值83,770,000美元，此前該公司在上個季度又購買了845,408股。聯合愛馬仕公司在第一季度將其在Turning Point Treeutics的地位提高了19.7%。聯合愛馬仕公司目前持有該公司2,075,037股股票，價值55,715,000美元，上一季度又購買了341,455股。最後，高盛公司在第一季度將其在轉折點治療公司的地位提高了5.4%。高盛股份有限公司現在持有該公司844,461股股票，價值22,674,000美元，該公司在上個季度又購買了43,252股。90.33%的股票由機構投資者和對衝基金持有。
Turning Point Therapeutics Stock Performance
轉折點治療公司股票表現
NASDAQ:TPTX opened at $76.01 on Friday. Turning Point Therapeutics, Inc. has a one year low of $23.77 and a one year high of $82.20. The stock has a market cap of $3.81 billion, a PE ratio of -11.02 and a beta of -0.18. The stock has a 50 day moving average price of $75.81 and a 200 day moving average price of $59.18.
納斯達克：多倫多證券交易所上週五開盤報76.01美元。Turning Point Treeutics，Inc.的一年低點為23.77美元，一年高位為82.20美元。該股市值為38.1億美元，市盈率為-11.02，貝塔係數為-0.18。該股的50日移動均價為75.81美元，200日移動均價為59.18美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
TPTX has been the topic of a number of recent analyst reports. Guggenheim set a $76.00 price target on Turning Point Therapeutics in a research report on Monday, June 20th. SVB Leerink downgraded Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $101.00 to $76.00 in a research report on Monday, June 13th. Nine equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $78.22.
TPTX一直是最近一些分析師報告的主題。古根海姆在6月20日星期一的一份研究報告中為Turning Point治療公司設定了76.00美元的目標價。SVB Leerink在6月13日(星期一)的一份研究報告中將Turning Point Treateutics的評級從“跑贏大盤”下調至“市場表現”，並將該股的目標價從101.00美元下調至76美元。九位股票研究分析師對該股的評級為持有，三位分析師對該公司股票的評級為買入。根據MarketBeat.com的數據，該公司目前的普遍評級為持有，平均目標價為78.22美元。
Insider Activity at Turning Point Therapeutics
轉折點治療公司的內部活動
In related news, CFO Paolo Tombesi sold 1,183 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $74.94, for a total value of $88,654.02. Following the completion of the sale, the chief financial officer now owns 28,700 shares of the company's stock, valued at $2,150,778. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 8.60% of the company's stock.
在相關新聞中，首席財務官保羅·湯貝西在7月27日星期三的一筆交易中出售了1,183股該公司股票。這隻股票的平均售價為74.94美元，總價值為88,654.02美元。出售完成後，首席財務官現在擁有28,700股公司股票，價值2,150,778美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過美國證券交易委員會網站。內部人士持有該公司8.60%的股份。
About Turning Point Therapeutics
關於轉折點療法
(Get Rating)
(獲取評級)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治療公司是一家臨牀階段的精確腫瘤學生物製藥公司，致力於設計和開發針對癌症遺傳驅動因素的治療方法。它開發了一系列酪氨酸激酶抑制劑(TKI)，針對TKI-NAI、̈Ve和TKI預治療患者的癌症基因驅動因素。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- 2 Regional Banks With Sector-Beating Price Performance
- MarketBeat: Week in Review 10/3-10/7
- ConAgra Brands Is A Value Pick For Income Investors
- 3 Stocks With Market-Beating Price Performance
- Lucid Motors May Test Investors' Resolve, But Should They Sell?
- 免費獲取StockNews.com關於轉折點治療(TPTX)的研究報告
- 2家地區性銀行的價格表現優於行業
- MarketBeat：回顧一週10/3-10/7
- 康尼格拉品牌是收益投資者的價值選擇
- 3只股價表現優於大盤的股票
- Lucid Motors可能會考驗投資者的決心，但他們應該出售嗎？
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《轉折點治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Turning Point Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。